— BioCryst Pharmaceuticals (NASDAQ: BCRX) reported a loss of $0.02 per share for the fourth quarter of 2019 vs. expected loss of $0.26 per share.
— Revenue was $39.7 million vs. $2.7 million in the fourth quarter of 2018 and targeted revenue of $9.88 million.
— R&D expenses increased to $26.8 million from $23.4 million in the prior-year quarter.
— For full-year 2020, operating cash use is expected to be in the range of $125 million to $150 million and operating expenses are estimated to be between $135 million and $160 million.
— On February 18, 2020, the company announced that the U.S. Food and Drug Administration (FDA) had accepted and filed its new drug application (NDA) for the approval of oral, once-daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.
— BioCryst expects Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to approve its berotralstat drug for the prophylactic treatment of HAE in the second half of 2020.
— BCRX stock rose about 7% in the pre-market trading session.
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
